succinate-ubiquinone oxidoreductase inhibitors (Meiji Seika)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug Namesuccinate-ubiquinone oxidoreductase inhibitors (Meiji Seika)
Drug Alias Nameatpenin A4atpenin Batpenin A5atpenins program (Meiji Seika Kaisha)mitochondrial complex II inhibitors (Meiji Seika Kaisha) +[7] 
ClassificationSmall molecules
Mechanisms of ActionSuccinate dehydrogenase inhibitors
TargetsSuccinate dehydrogenase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesMeiji Seika Pharmatech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMeiji Seika Pharmatech Co Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A